Related Experiment Videos
Drug-induced lupus erythematosus
Dimitar Antonov1, Jana Kazandjieva, Doncho Etugov
1Department of Dermatology and Venereology, Sofia Faculty of Medicine, Sofia, Bulgaria. dimitar_antonov@doctor.bg
Clinics in Dermatology
|July 6, 2004
Summary
Drug-induced lupus erythematosus (DILE) is a significant immune-mediated condition. This review explores its mechanisms, clinical presentations, and diagnostic criteria, focusing on drugs like minocycline and statins.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Drug-induced lupus erythematosus (DILE) is a significant immune-mediated disease.
- It is a widely commented upon and investigated condition among various drug-induced idiopathic immune-mediated diseases.
- Alternative terms include drug-related lupus, lupus-like syndrome, and lupus erythematosus medicamentosus.
Purpose of the Study:
- To review general aspects of drug-induced lupus erythematosus (DILE).
- To discuss pathogenic mechanisms, clinical forms, and diagnostic criteria for DILE.
- To provide detailed information on drugs implicated in DILE, such as minocycline, statins, and terbinafine.
Main Methods:
- Literature review of drug-induced lupus erythematosus.
- Analysis of pathogenic mechanisms and clinical manifestations.
- Examination of diagnostic criteria and implicated drugs.
Main Results:
- Drug-induced lupus erythematosus (DILE) encompasses various clinical presentations and pathogenic mechanisms.
- Established diagnostic criteria aid in identifying DILE.
- Specific drugs including minocycline, statins, and terbinafine are frequently associated with DILE.
Conclusions:
- Drug-induced lupus erythematosus (DILE) is a critical area of study within immune-mediated diseases.
- Understanding DILE's mechanisms, clinical features, and diagnostics is essential for patient care.
- Further research into implicated drugs can improve diagnosis and management of DILE.